SCHEMBL131302

SCHEMBL131302

NCC1CCCCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.54
SIGMAR1 Q99720 1/20 0.48
NCF1 P14598 1/20 0.46
PLG P00747 1/20 0.42
PLAT P00750 1/20 0.42
LMNA P02545 1/20 0.42
EPHX1 P07099 1/20 0.41
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
CHRM5 P08912 2/20 0.39
CYP1A2 P05177 1/20 0.39
ADRA2C P18825 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM1 P11229 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15444322 1.00 CYP2D6 (0.54) CYP2D6SIGMAR1NCF1PLGPLAT
SCHEMBL18102722 1.00 CYP2D6 (0.54) CYP2D6SIGMAR1NCF1PLGPLAT
SCHEMBL19992007 1.00 CYP2D6 (0.54) CYP2D6SIGMAR1NCF1PLGPLAT
SCHEMBL14417464 1.00 CYP2D6 (0.54) CYP2D6SIGMAR1NCF1PLGPLAT
SCHEMBL13893972 1.00 CYP2D6 (0.54) CYP2D6SIGMAR1NCF1PLGPLAT
SCHEMBL3536114 1.00 CYP2D6 (0.54) CYP2D6SIGMAR1NCF1PLGPLAT
Decarboxylated Derivative SCHEMBL9465 1.00
SCHEMBL19099823 1.00 CYP2D6 (0.54) CYP2D6SIGMAR1NCF1PLGPLAT
SCHEMBL22078896 1.00 CYP2D6 (0.54) CYP2D6SIGMAR1NCF1PLGPLAT
Decarboxylated Derivative SCHEMBL5183307 1.00 CYP2D6 (0.54) CYP2D6SIGMAR1NCF1PLGPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12246000-B2 Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides VILNIUS UNIVERSITY (LT) 2025-03-11 US disclosed
US-12043833-B2 Targeted compositions ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-23 US disclosed
US-20240132467-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE TMEM16A LIMITED (GB) 2024-04-25 US disclosed
US-20240000736-A1 INHIBITION OF PROTEIN AMYLOID AGGREGATION USING FLUORINATED BENZENESULFONAMIDES VILNIUS UNIVERSITY (LT) 2024-01-04 US disclosed
EP-4299062-A1 INHIBITION OF PROTEIN AMYLOID AGGREGATION USING FLUORINATED BENZENESULFONAMIDES Vilnius University (LT) 2024-01-03 EP disclosed
EP-4259607-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE TMEM16A LIMITED (GB) 2023-10-18 EP disclosed
CN-116745267-A Benzimidazole derivatives for the treatment of respiratory diseases 跨膜蛋白16A有限公司 2023-09-12 CN disclosed
US-11566025-B2 Viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-01-31 US disclosed
WO-2022266473-A1 SMALL MOLECULE DISRUPTORS OF PROTEIN INTERACTIONS IN HISTONE DEACETYLASE COMPLEXES DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-12-22 WO disclosed
CN-115124492-A Process for synthesizing tetraglycidyl amine epoxy resin by continuous method 上海华谊树脂有限公司 2022-09-30 CN disclosed
EP-0199986-B1 BENZISOSELENAZOLONYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1990-04-25 EP disclosed
US-4873350-A Diselenobis-benzoic acid amides of primary and secondary amines and processes for the treatment of diseases in humans caused by a cell injury A NATTERMANN & CIE GMBH (DE) 1989-10-10 US disclosed
EP-0198277-B1 DISELENO-BIS-BENZAMIDES OF PRIMARY AND SECONDARY AMINES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1989-05-03 EP disclosed
US-4774252-A ANTIINFLAMMATORY AGENTS A. NATTERMANN & CIE GMBH (DE) 1988-09-27 US disclosed
EP-0199986-A1 Benzisoselenazolonyl derivatives, process for their preparation and pharmaceutical compositions containing them A. Nattermann & Cie. GmbH (DE) 1986-11-05 EP disclosed
EP-0198277-A1 Diseleno-bis-benzamides of primary and secondary amines, processes for their production and pharmaceutical preparations containing them A. Nattermann & Cie. GmbH (DE) 1986-10-22 EP disclosed
US-4491671-A Process for the preparation of N-substituted imido-dicarboxylic acid diaryl esters BAYER AKTIENGESELLSCHAFT (DE) 1985-01-01 US disclosed
US-4348331-A FROM THE HYDROCHLORIDE OF A PRIMARY AMINE AND AN ARYL ESTER HALIDE BAYER AKTIENGESELLSCHAFT (DE) 1982-09-07 US disclosed
US-4024274-A Benzylamine derivatives and process for preparing them HOECHST AKTIENGESELLSCHAFT (DT) 1977-05-17 US disclosed
US-4001284-A PRIMARY AMINES, 2,4-DIPHENOXY-5-SULFAMOYLBENZOIC ACID HOECHST AKTIENGESELLSCHAFT (DT) 1977-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566025-B2 Viral replication inhibitors EIF2AK2, MAVS, ZC3HAV1 CYP2D6 3515/4885SIGMAR1 3557/4885NCF1 1198/4885
US-20240132467-A1 BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE TMEM109, CFTR, TMEM164 CYP2D6 1577/4885SIGMAR1 1082/4885NCF1 2618/4885
US-20240000736-A1 INHIBITION OF PROTEIN AMYLOID AGGREGATION USING FLUORINATED BENZENESULFONAMIDES APP, APBA1, IAPP CYP2D6 2920/4885SIGMAR1 3698/4885NCF1 2819/4885
US-12246000-B2 Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides APP, APBA1, IAPP CYP2D6 2920/4885SIGMAR1 3698/4885NCF1 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.